Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Audio on Optimizing Switch Strategies for Patients With Viral Suppression

In this on-demand recording of a live webinar, expert faculty discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy.
Daniel R. Kuritzkes, MD
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Released: June 10, 2021

In this episode, the first in a yearlong series on Key Decisions in HIV Care, Daniel R. Kuritzkes, MD, and Chloe Orkin, MBChB, FRCP, MD, discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy. Following their dialogue, the faculty field questions from healthcare professionals.

Presenters:

Daniel R. Kuritzkes, MD
Chief, Division of Infectious  
Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Chloe Orkin, MBChB, FRCP, MD
Professor of HIV  
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Clinical Care Options’ (CCO) commentary on patient education for people living with HIV during the COVID-19 pandemic

Sharon L. Walmsley, MSc, MD, FRCPC Released: September 22, 2021

From Dr. Eric S. Daar and Clinical Care Options (CCO), expert discussion on how new data from IAS 2021 expand our understanding of adverse events with specific ART regimens

Eric S. Daar, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: September 22, 2021 Expired: September 21, 2022

From Dr. Eric Daar and CCO, slides covering new data from IAS 2021 expanding our understanding of the adverse event profiles of specific ART regimens

Eric S. Daar, MD Released: September 22, 2021

Clinical Care Options (CCO): patient perspective on the decision to switch to long-acting injectable ART and the impact it has had on her life.

person default Anonymous Patient Released: September 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue